Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies

Fig. 1

Proportion of patients with enthesitis at baseline achieving full resolution over 104 weeks. Data shown for overall population (A), TNFi-naïve (B), and TNFi-IR (C) subpopulations. n, number of patients with enthesitis at baseline. Proportion of patients with resolution at weeks 16, 52, and 104 were based on the survival analysis (Kaplan-Meϊer estimates) at days 112, 365, and 729, respectively. Placebo patients were censored at day 168 of follow-up. EC, enthesitis count; FR, full resolution; IR, inadequate responder; SEC, secukinumab; TNFi, tumor necrosis factor inhibitor

Back to article page